Matteo Duca

Safety and Antitumor Activity of the Multitargeted Pan-TRK, ROS1, and ALK Inhibitor Entrectinib: Combined Results from Two Phase I Trials (ALKA-372-001 and STARTRK-1)

Alexander Drilon, Salvatore Siena, Sai‐Hong Ignatius Ou et al. · Cancer Discovery · 2017 · 795 citations · Full text

Phase I/IIa Trial of BMS-986148, an Anti-mesothelin Antibody-drug Conjugate, Alone or in Combination with Nivolumab in Patients with Advanced Solid Tumors

Sylvie Rottey, Jeffrey Clarke, Kyaw Aung et al. · EUR Research Repository (Erasmus University Rotterdam) · 2022 · 50 citations · Full text

EGFR tyrosine kinase inhibitors beyond focal progression obtain a prolonged disease control in patients with advanced adenocarcinoma of the lung

Fabio Conforti, Chiara Catania, Francesca Toffalorio et al. · Lung Cancer · 2013 · 44 citations

Oncology, Advanced Lung Disease, Advanced Adenocarcinoma +8

Expression of NY-ESO-1, MAGE-A3, PRAME and WT1 in different subgroups of breast cancer: An indication to immunotherapy?

Anna Tessari, Lorenzo Pilla, Silvia Damian et al. · The Breast · 2018 · 36 citations

Different Subgroups, Breast Oncology, Medicine +6

Molecular Tumor Board as a Clinical Tool for Converting Molecular Data Into Real-World Patient Care

Andrea Vingiani, Luca Agnelli, Matteo Duca et al. · JCO Precision Oncology · 2023 · 22 citations · Full text